A study to evaluate the reduced dose of abiraterone acetate with concomitant low-dose prednisone in the treatment of > or= 85 year-old patients with advanced castrate-resistant prostate cancer.

Trial Profile

A study to evaluate the reduced dose of abiraterone acetate with concomitant low-dose prednisone in the treatment of > or= 85 year-old patients with advanced castrate-resistant prostate cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2015

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top